Today’s Research Reports on Trending Tickers: Merck & Co., and Bristol-Myers Squibb
U.S. equities plunged on Thursday as worries over global growth weighed on the broader market and investors continued to digest the minutes from the Federal Reserve. The Dow Jones Industrial Average shed 1.27 percent to close at 25,379.45, while the S&P 500 Index dropped 1.44 percent to close at 2,768.78. The Nasdaq Composite Index declined 2.06 percent to close at 7,485.14.
"To me, this reflects a lack of trust in the Federal Reserve," said president at Icon Funds, Craig Callahan. "The market fears the Fed will over-tighten," he added.
RDI Initiates Coverage on:
Merck & Co., Inc.
Bristol-Myers Squibb Company
Merck & Co.’s stock moved 0.54% higher Thursday, to close the day at $72.21. The stock recorded a trading volume of 12,225,953 shares, which was above its three months average volume of 8,247,364 shares. In the last year, Merck & Co.’s shares have traded in a range of 52.83 – 72.89. The share price has gained 36.68% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $70.25 is above its 200-day moving average of $63.66. Shares of the company are trading at a Price to Earnings ratio of 148.89. Shares of Merck & Co. have gained roughly 2.54 percent in the past month and are up 28.33 percent year-to-date.
Access RDI’s Merck & Co., Inc. Research Report at:
On Thursday, shares of Bristol-Myers Squibb recorded a trading volume of 13,606,648 shares, which was above the three months average volume of 5,803,563 shares. The stock ended the day 4.96% lower at $55.98. The share price has fallen 20.09% from its 52 week high with a 52 week trading range of 49.96 – 70.05. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $60.99 is above its 200-day moving average of $57.03. Shares of the company are trading at a Price to Earnings ratio of 248.80. Shares of Bristol-Myers Squibb have fallen roughly 8.95 percent in the past month and are down 8.65 percent year-to-date.
Access RDI’s Bristol-Myers Squibb Company Research Report at:
Our Actionable Research on Merck & Co., Inc. (NYSE:MRK) and Bristol-Myers Squibb Company (NYSE:BMY) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.